Clinical Observation Report on Trans-Arterial Stem Cell Infusion in Liver Cirrhosis

Clinical Observation Report on Trans-Arterial Stem Cell Infusion in Liver Cirrhosis

Conducted by: Viecell Institute of Regenerative Medicine
Observation Period: 6–12 months post-infusion
Therapy Used: Trans-Arterial Stem Cell Infusion (Viecell Protocol)

Introduction

Liver cirrhosis represents the final common pathway of chronic liver injury, leading to fibrosis, portal hypertension, and hepatic failure. Traditional management focuses on symptom control, with liver transplantation being the only curative option — an expensive, invasive, and life-altering procedure.

Viecell Institute has pioneered a Trans-Arterial Stem Cell Infusion (TASCI) protocol, delivering stem cells directly into the hepatic artery to promote hepatic regeneration, fibrosis reversal, and improved hepatic function.

This observational report consolidates outcomes in patients with Alcoholic and Non-Alcoholic Liver Cirrhosis, the latter further subdivided into:

1. Autoimmune Hepatitis–Induced Cirrhosis
2. Lifestyle Disorder–Related Cirrhosis (NAFLD/NASH)
3. Virus-Induced Cirrhosis (HBV/HCV)

Category-Wise Report

1. Alcoholic Liver Cirrhosis

• Observation Period: 6–12 months
• Gender Distribution: 78% Male, 22% Female
• Age Categories:
  • 18–45 years: Outstanding results
  • 45–65 years: Good improvement
  • 65+ years: Satisfactory response

Observations:

• Reduction in serum bilirubin and improvement in albumin levels within 8 weeks.
• Ultrasound showed regression in fibrotic bands and improved hepatic echotexture.
• Fatigue, jaundice, and ascites significantly reduced in most patients.
• 80% of transplant-advised patients avoided surgery post-therapy.
• Patient Impact:
  Participants reported renewed energy, appetite, and quality of life, describing the therapy as “a preferred option to liver transplant.”

2. Non-Alcoholic Liver Cirrhosis

A. Autoimmune Hepatitis–Induced Cirrhosis

• Gender Distribution: 40% Male, 60% Female
• Response by Age:
  • 18–45 years: Outstanding
  • 45–65 years: Good
  • 65+ years: Satisfactory

Observations:

• Reduction in autoimmune markers and transaminase levels.
• Noticeable structural recovery on FibroScan in younger cohort.
• Improved tolerance to immunosuppressive drugs post-therapy.

B. Lifestyle Disorder–Related Cirrhosis (NAFLD/NASH)

• Gender Distribution: 65% Male, 35% Female
• Response by Age:
  • 18–45 years: Outstanding
  • 45–65 years: Good
  • 65+ years: Satisfactory

Observations:

• Normalization of liver enzymes in >70% cases.
• Radiological evidence of improved liver density and vascularity.
• Enhanced metabolic parameters (reduced fasting glucose and cholesterol).
• Marked improvement in energy levels and digestive function.

---

C. Virus-Induced Cirrhosis (Hepatitis B/C)

• Gender Distribution: 72% Male, 28% Female
• Response by Age:
  • 18–45 years: Outstanding
  • 45–65 years: Good
  • 65+ years: Satisfactory

Observations:

• Stable viral load with significant histological recovery.
• Improved albumin synthesis and coagulation profiles.
• Better response in patients already on antiviral therapy.

    Overall Outcomes

Age Group	Response	Functional Improvement	Fibrosis Regression	Transplant Avoidance
18–45 years	Outstanding	>85%	>70%	90%
45–65 years	Good	~65%	~50%	75%
65+ years	Satisfactory	~45%	~30%	60%

Conclusion

Viecell’s Trans-Arterial Stem Cell Infusion Protocol has demonstrated remarkable regenerative potential in both Alcoholic and Non-Alcoholic liver cirrhosis patients.
Patients once advised for liver transplantation have experienced reversal of fibrosis, normalization of liver function, and improved quality of life, eliminating the need for invasive and costly transplant surgeries.

In summary:
Stem Cell Therapy through the Trans-Arterial route is emerging as a safe, effective, and transformative option for chronic liver failure and cirrhosis management.